Community Research and Development Information Service - CORDIS

  • European Commission
  • CORDIS
  • Projects and Results
  • Periodic Reporting for period 1 - ATx201 (A novel class of antibiotics for treatment of infected atopic dermatitis: an innovative solution for a significant unmet medical need)
H2020

ATx201 Report Summary

Project ID: 736508

Periodic Reporting for period 1 - ATx201 (A novel class of antibiotics for treatment of infected atopic dermatitis: an innovative solution for a significant unmet medical need)

Reporting period: 2016-08-01 to 2016-11-30

Summary of the context and overall objectives of the project

Infections in atopic dermatitis (AD) is associated with significant co-morbidity. AntibioTx`s ATx201 is an innovative solution which acts as an antimicrobial. The objectives of the project is to verify the promise of the drug product and commercial scale-up to bring the solution to market.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

The current stage of development of the proposed solution aligns with a Technology Readiness Level 7 since the drug compound had been tested on human subject volunteers. The project helped to establish the definition development plans for ATx201. This includes assessment of regulatory route, interaction with regulatory consultants and competent authorities, as well as clinical study design to bring forward its market authorisation agenda. This process has been developed with clinical advisors and KOLs within dermatology.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

The solution solves critical issues related to effective and safe treatment of skin infections. ATx201 offers 1) better treatment due to effect against resistant bacteria; 2) potential for repetitive and long term effective treatment of infected AD due to significantly reduced resistance mutation frequency; as well as 3) reduced need for oral treatment and systemic exposure and toxicity. ATx201 has the potential to change the treatment paradigm of dermatological infections by providing an effective, non-systemic treatment.

Related information

Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top